(Indacaterol + mometasone furoate) is a Small Molecule owned by Novartis, and is involved in 13 clinical trials, of which 11 were completed, 1 is ongoing, and 1 is planned.

Atectura Breezhaler (QMF-149) is a combination of Indacaterol, a long-acting beta2-adrenergic agonist and mometasone. Indacaterol binds beta 2 adrenergic receptors in bronchial smooth muscle and stimulates intracellular adenyl cyclase, thereby increasing the production of cyclic adenosine monophosphate (cAMP). Increased cAMP levels cause relaxation of bronchial smooth muscle, improve mucociliary clearance and reduce mediator substance release in inflammatory cells, especially from mast cells. Mometasone is a medium-potency synthetic corticosteroid with antiinflammatory, antipruritic, and vasoconstrictive properties. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.

The revenue for (Indacaterol + mometasone furoate) is expected to reach a total of $1.2bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the (Indacaterol + mometasone furoate) NPV Report.

(Indacaterol + mometasone furoate) was originated by Novartis and Schering-Plough and is currently owned by Novartis.

(Indacaterol + mometasone furoate) Overview

Indacaterol and Mometasone Furoate (Atectura, Atectura Breezhaler, Bemrist Breezhaler) is a fixed dose combination of long acting beta2-adrenergic agonist and inhaled corticosteroid. It is formulated as hard gelatin capsules for inhalational route of administration. It is indicated as a once-daily maintenance treatment of asthma in adults and adolescents 12 years of age and older with reversible obstructive airways disease.

QMF-149 is under development for the treatment of asthma. The drug candidate is an inhaled formulation. QMF149 combines QAB149 (indacaterol) with mometasone and developed on Twisthaler inhalation system. QAB149 targets beta2-adrenergic receptor and glucocorticoid receptor. It was under development for the treatment of chronic obstructive pulmonary disease (COPD).

Novartis Overview

Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.

The company reported revenues of (US Dollars) US$52,877 million for the fiscal year ended December 2021 (FY2021), an increase of 6% over FY2020. In FY2021, the company’s operating margin was 22.1%, compared to an operating margin of 20.3% in FY2020. In FY2021, the company recorded a net margin of 45.4%, compared to a net margin of 16.2% in FY2020. The company reported revenues of US$12,842 million for the third quarter ended September 2022, a decrease of 1.9% over the previous quarter.

Quick View – (Indacaterol + mometasone furoate)

Report Segments
  • Innovator (Non-NME)
Drug Name
  • (Indacaterol + mometasone furoate)
Administration Pathway
  • Inhalational
Therapeutic Areas
  • Respiratory
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.